Sanofi Expands Adult Vaccines with Dynavax Acquisition

Sanofi completes Dynavax acquisition, strengthening its push into adult vaccines and expanding its global immunization footprint.

The R&D-based, AI-powered biopharma enterprise has announced this afternoon that it has closed the deal, and Dynavax Technologies Corporation became a part of the umbrella. The deal incorporates commercially available hepatitis B vaccine, HEPLISAV-B, and shingles vaccine candidate, Z-1018, among other early-stage pipeline programs of Dynavax.

HEPLISAV-B is licensed and commercially used in the USA to prevent hepatitis B in adults. It can distinguish itself with a two-dose plan to be administered in a month, which provides quicker schedule than the conventional ones. Z-1018 is a shingles vaccine candidate of Dynavax that is under Phase 1/2 trials.

Also Read: Advancing Interventional Radiology in India Through Collaboration

The tender offer for all outstanding shares of Dynavax common stock expired shortly after 11:59 p.m. EST on February 9, 2026.  Every necessary requirement was fulfilled. Sanofi will pay all duly tendered shares on February 10, 2026, and will pay in cash without interest and liable to withholding tax an amount equal to $15.50 per share.

After the tender offer, Sanofi finalized the merger by a wholly owned subsidiary following the Delaware law. Dynavax remains the remaining corporation and it becomes now indirect and wholly owned subsidiary of Sanofi. The shares that were not tendered were converted into the right to get the same price of shares of 15.50 in form of cash. By February 10, 2026, common stock of the Dynavax has been removed off the NASDAQ Global Select Market.

Sanofi claimed that Dynavax acquisition complements its adult vaccination line with combining the Dynavax vaccinations with its commercial abilities and development capabilities.